Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping "MAESTRO"

Completed

Phase 4 Results N/A

Update History

18 Mar '15
Trial name was updated.
New
Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
30 Jan '13
A location was updated in Wonju-si.
New
The overall status was removed for Department of Neurology, Wonju Christian Hospital, Yonei University Wonju College of Medicine.
A location was updated in Goyang-si.
New
The overall status was removed for Department of Neurology, National Health Insurance Corporation Ilsan Hospital.
A location was updated in Seongnam-si.
New
The overall status was removed for Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine.
A location was updated in Changwon.
New
The overall status was removed for Changwon Fatima Hospital.
A location was updated in Daegu.
New
The overall status was removed for Kyungpook National University Hospital.
A location was updated in Daegu.
New
The overall status was removed for Keimyung University Dongsan Medical Center.
A location was updated in Daegu.
New
The overall status was removed for Yeungnam University Hospital.
A location was updated in Daejeon.
New
The overall status was removed for Department of Neurology, Konyang University Hospital.
A location was updated in Gwangju.
New
The overall status was removed for Department of Neurology, Chosun University Hospital.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Kyung Hee University Hospital at Gangdong.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Korea University Guro Hospital.
A location was updated in Seoul.
New
The overall status was removed for Korea University Anam Hospital.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, National Medical Center.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Severance Hospital, Yonsei University College of Medicine.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Ewha Womans University Mokdong Hospital.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Sanggye Paik Hospital, Inje University College of Medicine.
A location was updated in Seoul.
New
The overall status was removed for Department of Neurology, Gangnam Severance Hospital, Yonsei Univ. College of Medicine.
A location was updated in Seoul.
New
The overall status was removed for KyungHee University Medical Center.
26 Apr '12
A location was updated in Gunpo.
New
The overall status was updated to "Withdrawn" at Department of Neurology, WonKwang University Sanbon Hospital.
A location was updated in Daegu.
New
The overall status was removed for Yeungnam University Hospital.
6 Oct '11
The eligibility criteria were updated.
New
Inclusion Criteria: 1. Patients who have non-cardiogenic ischemic stroke of TOAST classification within 30 days prior to screening 2. ≥ 20 years of age; adult, at the date of signing the informed consent 3. Written informed consent Exclusion Criteria: 1. History for bleeding tendency or recent major bleeding within 2 weeks 2. Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl) 3. Thrombocytopenia (platelet < 100,000mm3) 4. Any contraindication of antiplatelet agent 5. Severe congestive heart failure 6. Patients who need to take anticoagulants or two or more antiplatelet agents 7. Severe concomitant disease with the expected survival less than 2 years 8. Pregnant or nursing 9. Any drug clinical trials within 30 days of signing the informed consent
Old
Inclusion Criteria: 1. Patients who have non-cardiogenic ischemic stroke of TOAST classification within 30 days prior to screening 2. ? 20 years of age; adult, at the date of signing the informed consent 3. Written informed consent Exclusion Criteria: 1. History for bleeding tendency or recent major bleeding within 2 weeks 2. Chronic liver disease (ALT > 100 IU/L or AST > 100 IU/L) or renal dysfunction (creatinine > 4.0 mg/dl) 3. Thrombocytopenia (platelet < 100,000mm3) 4. Any contraindication of antiplatelet agent 5. Severe congestive heart failure 6. Patients who need to take anticoagulants or two or more antiplatelet agents 7. Severe concomitant disease with the expected survival less than 2 years 8. Pregnant or nursing 9. Any drug clinical trials within 30 days of signing the informed consent